Over two-thirds of biopharmaceutical manufacturers now report that their facility is experiencing capacity bottlenecks due to downstream processing. A number of factors continue to converge to create ...
One of the most important bioprocessing advances in recent years has been the rise in levels of manufactured therapeutic proteins. Indeed, the overall average yield reported for commercial monoclonal ...
Milestone Marks Completion of First Phase of Two-Part Myford Facility Expansion; First Customer Project to Begin in New Downstream Processing Suite in Coming Month TUSTIN, Calif., Jan. 10, 2022 (GLOBE ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results